Related references
Note: Only part of the references are listed.Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives
D. Chen et al.
CURRENT CANCER DRUG TARGETS (2011)
Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics
Camilla Krakstad et al.
MOLECULAR CANCER (2010)
Inhibition of PI3K by ZSTK474 suppressed tumor growth not via apoptosis but G0/G1 arrest
Shingo Dan et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2009)
Advances in Development of Phosphatidylinositol 3-Kinase Inhibitors
Dexin Kong et al.
CURRENT MEDICINAL CHEMISTRY (2009)
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM)
D Yin et al.
ONCOGENE (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
The prognostic significance of phosphatidylinositol 3-kinase pathway activation in human gliomas
A Chakravarti et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Targeting the PI3K-Akt pathway in human cancer: Rationale and promise
J Luo et al.
CANCER CELL (2003)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Proteasome inhibition: a new strategy in cancer treatment
J Adams et al.
INVESTIGATIONAL NEW DRUGS (2000)
Share Paper
